title: Arrhythmia and reduced heart rate variability during pregnancy in women with congenital heart disease and previous reparative surgery.
abstract: OBJECTIVE
  Tachyarrhythmia during pregnancy may have an adverse effect on the mother and the fetus. Heart rate variability (HRV) is a significant marker of autonomic nervous function and may predict tachyarrhythmia. HRV and incidence of arrhythmia in women with repaired congenital heart disease (CHD) during pregnancy were examined.
  
  
  METHODS
  Twenty-eight patients with repaired CHD (35 pregnancies, age: 26+/-3.5 years at their first pregnancy, 22+/-6.2 years post-repair) and 19 healthy pregnant volunteers (controls, 19 pregnancies, age: 28+/-5.5 years) were enrolled. Holter monitoring and laboratory tests were examined at 28+/-4 weeks of gestation and 22+/-13 weeks postpartum in patients and 28+/-3 weeks of gestation in controls. Time and frequency variables of HRV were analyzed.
  
  
  RESULTS
  Compared with controls and postpartum, there was a significantly higher incidence of tachyarrhythmia during pregnancy in women with CHD (4 episodes of supraventricular tachyarrhythmia (SVT) and 5 of non-sustained ventricular tachycardia, P=0.02). HR response in tetralogy of Fallot was impaired (781+/-50 ms, P=0.02). Most of HRV variables were significantly suppressed (average RR 740+/-64 ms, SDRR 99+/-22 ms, low and high frequency domains (341+/-165 ms2 and 256+/-181 ms2) (P<0.05). Reduced SDRR and high frequency domains were observed in patients with tachyarrhythmia. Furthermore, there were increased left ventricular end-diastolic dimensions 48+/-5 mm (P=0.001) and atrial natriuretic peptide levels 33+/-13 pg/ml (P=0.01) in the CHD patients compared with postpartum levels.
  
  
  CONCLUSIONS
  Impaired autonomic nervous activity, volume overload of the heart and operative scar all play a contributory role in higher incidence of tachyarrhythmia during pregnancy in patients with repaired CHD compared to healthy pregnant controls. Close monitoring of patients with CHD for tachyarrhythmia during pregnancy is, thus, warranted.
authors.affiliation: Department of Pediatrics, Chiba Cardiovascular Center, Japan. KNIWA@aol.com
authors.forename: Koichiro
authors.initials: K
authors.lastname: Niwa
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tateno
authors.forename: Teiji
authors.initials: T
authors.lastname: Akagi
authors.forename: Wakako
authors.initials: W
authors.lastname: Himeno
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Kawasoe
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Tatebe
authors.forename: Kozo
authors.initials: K
authors.lastname: Matsuo
authors.forename: Michael A
authors.initials: MA
authors.lastname: Gatzoulis
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakazawa
mesh_terms: D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood; D001341:Autonomic Nervous System / Q000503:physiopathology; D015716:Electrocardiography, Ambulatory; D005260:Female; D006330:Heart Defects, Congenital / Q000453:epidemiology / Q000503:physiopathology* / Q000601:surgery; D006339:Heart Rate / Q000502:physiology*; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000453:epidemiology / Q000503:physiopathology*; D013610:Tachycardia
chemical_list: D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor